Neurizon Therapeutics has appointed a new Chief Financial Officer to strengthen its leadership as it prepares to advance its lead drug candidate, NUZ 001, through late-stage clinical trials and to build readiness for future commercialisation.

Bioxyne has secured a two-year supply agreement worth up to $50 million with German pharmaceutical company ADREXpharma GmbH, a move the Australian firm says will give it a defined pathway into Europe and near-term revenue visibility.

The board confirmed the promotion from her role as Chief Operating Officer, which she took up in 2023 after more than 18 years at Hexima, where she helped advance that company's lead drug candidate through preclinical and clinical development.

Noxopharm has engaged a global clinical research organisation to strengthen its US regulatory strategy and prepare for a pre-Investigational New Drug meeting with the US Food and Drug Administration.

Algorae Pharmaceuticals has announced that it has executed an agreement with Torrent Pharmaceuticals to commercialise two prescription molecules in Australia and New Zealand.

PYC Therapeutics has dosed the first patient in a Phase 1b Multiple Ascending Dose study testing PYC-003 in people with polycystic kidney disease.

Moderna has opened applications for the 2026 Moderna Australia Fellowship, a program that will fund and mentor early-career Australian scientists for two years as they pursue mRNA research and innovation.

AdAlta has raised $2.5 million from sophisticated investors to accelerate development of its lead CAR T therapy, BZDS1901, and to progress manufacturing and regulatory milestones in Australia and the United States.

The cash injection is intended to strengthen Cynata’s runway through two near-term clinical milestones and to position the company for commercial partnering and regulatory engagement after results are released.

Arovella Therapeutics has updated investors, advising that a requisitioning shareholder had served a notice under the Corporations Act seeking the removal of two directors and that the company would undergo a significant board refresh.

Botanix Pharmaceuticals has announced the promotion of Paul Seaback to Chief Operating Officer, a move the commercial dermatology company said will strengthen day-to-day operations and drive strategic growth across its Philadelphia and Phoenix businesses.

Entropy Neurodynamics has reported Phase 2a results suggesting a potential new direction for patients with treatment-resistant irritable bowel syndrome.

Telix Pharmaceuticals is positioning a new generation of PSMA-targeted therapies to overcome limitations seen when first-generation radioligand therapies are moved into earlier lines of prostate cancer care.

Syntara CEO Gary Phillips said, “We’re very grateful for the strong support from our shareholders and new investors in this capital raising, stemming from the positive FDA review of our clinical development plan and Phase 2b protocol for amsulostat."

Mesoblast has reached a key milestone in its bid to bring a non-opioid, disease-modifying treatment for chronic low back pain to market, announcing that the pivotal Phase 3 trial of rexlemestrocel L has hit its patient recruitment target.

AVITA Medical has secured regulatory clearance in Australia and a WAND listing in New Zealand for RECELL GO, its next-generation system for preparing RECELL Spray On Skin.

Emyria has reached an agreement with Matilda Healthcare to open an Empax clinic at Matilda Nepean Private Hospital in Kingswood, expanding the company's presence in New South Wales and increasing its national footprint.